The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)


The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.

Full Title of Study: “A Randomized, Double-Masked, Dose-Ranging, Multi-Center, Phase II Study Comparing the Safety and Efficacy of OT-551 With Placebo to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: February 2010

Detailed Description

Age-related macular degeneration (AMD) results in severe, irreversible central vision loss and is the leading cause of blindness in individuals older than 50 years in the western world. The vast majority of AMD patients have the 'dry' (non-exudative) form that is characterized by the presence of drusen and atrophic changes in the retinal pigment epithelium (RPE). Dry AMD may remain static or progress slowly to produce areas of geographic atrophy (GA), the advanced or late-stage form of dry AMD. GA is a severe vision-threatening lesion of the macula that may impair visual function, impact daily life activities, and result in blindness. Currently, there is no approved treatment for dry AMD or GA. Pre-clinical results have shown that OT-551 may protect RPE cells and photoreceptors from oxidative damage and block angiogenesis stimulated by VEGF and other growth factors, and therefore is a therapeutic candidate for treating GA.


  • Drug: OT-551
    • OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
  • Drug: OT-551
    • OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
  • Drug: vehicle placebo
    • OT-551 0% ophthalmic solution, 2 drops 4 times daily

Arms, Groups and Cohorts

  • Experimental: 1
    • OT-551 0.3% ophthalmic solution
  • Experimental: 2
    • OT-551 0.45% ophthalmic solution
  • Placebo Comparator: 3
    • vehicle placebo

Clinical Trial Outcome Measures

Primary Measures

  • Change in the area of GA
    • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

  • have a clinical diagnosis of GA in one or both eyes;
  • be of non-childbearing potential

Exclusion Criteria

  • have GA secondary to any condition other than AMD in the study eye;
  • have a BCVA of 20/200 or worse in the non-study eye;
  • have a history of or current choroidal neovascularization in either eye, or the need for any study eye anti-angiogenic therapy;
  • have any ocular condition in the study eye that would progress during the course of the study and could affect central vision or other ocular conditions that may be a confounding factor in this study;
  • need to wear contact lenses in the study eye during the study;
  • had confounding ocular surgery in the study eye;
  • have concomitant treatment with any systemic or ocular medication that is known to be toxic to the lens, retina, or optic nerve;

Gender Eligibility: All

Minimum Age: 55 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Othera Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Alison Brown, Othera Pharmaceuticals, Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.